ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

Compare

538 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SPRY Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

ARS

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SPRY Stock 12 Month Forecast

Average Price Target

$32.50

▲(209.82% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for ARS Pharmaceuticals in the last 3 months. The average price target is $32.50 with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 209.82% change from the last price of $10.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","36":"$36","14.25":"$14.25","21.5":"$21.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,11.36923076923077,13.338461538461539,15.307692307692308,17.276923076923076,19.246153846153845,21.215384615384615,23.184615384615384,25.153846153846153,27.123076923076923,29.092307692307692,31.06153846153846,33.03076923076923,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,11.176923076923078,12.953846153846154,14.730769230769232,16.50769230769231,18.284615384615385,20.06153846153846,21.838461538461537,23.615384615384617,25.392307692307696,27.169230769230772,28.946153846153848,30.723076923076924,{"y":32.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.4,10.984615384615385,12.56923076923077,14.153846153846155,15.73846153846154,17.323076923076925,18.907692307692308,20.492307692307694,22.07692307692308,23.661538461538463,25.246153846153845,26.830769230769235,28.415384615384617,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$32.50

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/25/25

ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy RatingWe believe the company has driven meaningful demand for neffy in recent months that should continue to grow and translate to prescriptions and revenue over the coming quarters as several commercial initiatives gain momentum. While the company has secured good coverage for neffy, lowering an important barrier to broad prescribing, it still has more work to do to remove barriers to prescribing for more patients; a recently announced FDA workshop on December 16 focused on enhancing access to epinephrine may help drive additional coverage. In the meantime, we believe the recent Get neffy on Us program should help while waiting for additional payers to come online. We continue to see blockbuster potential for neffy and believe the company is well funded to support the launch, so we rate shares Outperform.

Kyle Bauser

Roth MKM

$30

Buy

185.99%

Upside

Reiterated

11/11/25

Roth MKM Remains a Buy on ARS Pharmaceuticals (SPRY)We reiterate our Buy rating and $30 PT.

Andreas Argyrides

Oppenheimer

$40→$35

Buy

233.65%

Upside

Reiterated

11/10/25

ARS Pharmaceuticals (SPRY) Gets a Buy from OppenheimerBrings our price target down from $40 to $35 following strong 3Q25 financials.

Ryan Deschner

Raymond James

―

Buy

―

Reiterated

09/26/25

ARS Pharmaceuticals Gains Momentum: Buy Rating Justified by Market Share and Script Volume Increase

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

138.32%

Upside

Reiterated

09/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

166.92%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

185.99%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/25/25

Kyle Bauser

Roth MKM

$30

Buy

185.99%

Upside

Reiterated

11/11/25

Roth MKM Remains a Buy on ARS Pharmaceuticals (SPRY)We reiterate our Buy rating and $30 PT.

Andreas Argyrides

Oppenheimer

$40→$35

Buy

233.65%

Upside

Reiterated

11/10/25

ARS Pharmaceuticals (SPRY) Gets a Buy from OppenheimerBrings our price target down from $40 to $35 following strong 3Q25 financials.

Ryan Deschner

Raymond James

―

Buy

―

Reiterated

09/26/25

ARS Pharmaceuticals Gains Momentum: Buy Rating Justified by Market Share and Script Volume Increase

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

138.32%

Upside

Reiterated

09/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

166.92%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

185.99%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ARS Pharmaceuticals

1 Month

xxx

Success Rate

9/11 ratings generated profit

Average Return

+16.92%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 81.82% of your transactions generating a profit, with an average return of +16.92% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+7.89%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.89% per trade.

1 Year

Andreas ArgyridesOppenheimer

Success Rate

8/11 ratings generated profit

Average Return

+90.75%

reiterated a buy rating last month

Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +90.75% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+100.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +100.03% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SPRY Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SPRY has received 5 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. SPRY average Analyst price target in the past 3 months is 32.50.

Each month's total comprises the sum of three months' worth of ratings.

SPRY Financial Forecast

SPRY Earnings Forecast

Next quarter’s earnings estimate for SPRY is -$0.42 with a range of -$0.57 to -$0.24. The previous quarter’s EPS was -$0.52. SPRY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SPRY has Performed in-line its overall industry.

SPRY Sales Forecast

Next quarter’s sales forecast for SPRY is $26.25M with a range of $21.80M to $31.92M. The previous quarter’s sales results were $32.50M. SPRY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SPRY has Performed in-line its overall industry.

SPRY Stock Forecast FAQ

What is SPRY’s average 12-month price target, according to analysts?

Based on analyst ratings, ARS Pharmaceuticals’s 12-month average price target is 32.50.

What is SPRY’s upside potential, based on the analysts’ average price target?

ARS Pharmaceuticals has 209.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SPRY a Buy, Sell or Hold?

ARS Pharmaceuticals has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is ARS Pharmaceuticals’s price target?

The average price target for ARS Pharmaceuticals is 32.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $30.00. The average price target represents 209.82% Increase from the current price of $10.49.

What do analysts say about ARS Pharmaceuticals?

ARS Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of SPRY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

SPRY Analyst Ratings

SPRY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ARS Pharmaceuticals

SPRY Analyst Recommendation Trends

SPRY Financial Forecast

SPRY Earnings Forecast

SPRY Sales Forecast

SPRY Stock Forecast FAQ

Detailed List of Analyst Forecasts